A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

* Inclusion Criteria: * Provide written informed consent before any study assessment is performed. * Male or female at least 18 years of age at screening. * Chronic plaque psoriasis history ≥ 6 months;At the time of randomization, moderate to severe plaque psoriasis. * Subject is a candidate for systemic psoriasis therapy and/or phototherapy and/or chemo phototherapy. * The body mass index (BMI) was ≥18 kg/m2 and ≤35 kg/m2 at screening. * Exclusion Criteria: * Diagnosis of psoriasis at screening is not chronic plaque psoriasis * Severe infection or systemic infection before baseline * There are other skin problems that researchers believe will hinder the evaluation of psoriasis. * Subject has a history or symptom of malignancy within 5 years prior to screening, regardless of whether or not treatment has been received, with or without signs of recurrence or metastasis. * The investigators believe that the subject is not suitable for any clinical condition involved in the clinical study. * Those who are allergic to the study ingredients or excipients, or who are allergic to other biological agents. * There is evidence that hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) confirmation test is positive. * Subject's medical history, symptoms and examination results suggest active tuberculosis or latent tuberculosis. * Laboratory tests have clinical implications at screening, and the investigators believe that participation in the study may pose unacceptable risks to the subject or impede data analysis. * Women who are pregnant or breastfeeding at screening or at baseline * The investigator believes that it will prevent the subject from following and completing any other circumstances of the study protocol.